ClinicalTrials.gg
CompletedNCT00851084AFFIRMUpdated Jun 7, 2016Results posted

Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer

A Phase 2 interventional study of aflibercept and oxaliplatin in Colorectal Neoplasms and Neoplasm Metastasis, sponsored by Sanofi. Completed at 37 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-07.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
268
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 24 studies testing aflibercept in Colorectal Neoplasms — 1 open to participants now, 2 under way, none of them phase 3. aflibercept · Colorectal Neoplasms.

Enrollment
4th of 24
268 · median 63
Started
2009
with 1 other
Phase 2
14 of 24
none open now
Registered
2nd of 24
by date
Lead sponsor
8 of 24
Sanofi

Among the 24 studies testing aflibercept in Colorectal Neoplasms, this one is the 4th largest by enrollment, is one of 2 that started in 2009, is one of 14 in phase 2, and was the 2nd registered.

Colorectal Neoplasms

6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

1 of the 24 studies testing aflibercept in Colorectal Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing aflibercept in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The primary objective of the study is to estimate the progression-free survival rate at 12 months for the two arms of the study.

Secondary objectives include the evaluation of overall objective response rate to treatment, progression-free survival, overall survival, safety and documentation of potential immunogenicity of aflibercept.

This study was a non-comparative randomized trial and was not powered for a comparison of any of the efficacy endpoints.

Rather, the aim of the trial was to get, for all endpoints, an estimation of the efficacy and safety of aflibercept combined with a modified FOLFOX6 regimen. In such type of non-comparative randomized trial, the control FOLFOLX6 arm was intended to only act as a check on the similarity of the current patients to the historical controls with respect to clinical outcome when given FOLFOX6 treatment.

03

Conditions studied

  • Colorectal Neoplasms
  • Neoplasm Metastasis

Keywords

  • Angiogenesis
  • Colon cancer
  • Rectal cancer
  • Oxaliplatin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven adenocarcinoma of the colon or the rectum
  • disease not amenable to potentially curative treatment

Exclusion criteria

Exclusion Criteria:

  • Prior therapy for cancer of the colon or the rectum
  • Prior treatment with angiogenesis inhibitors

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
268 participants (actual)

Study arms

  • Active comparator
    mFOLFOX6 only

    modified FOLFOX6 chemotherapy regimen

    Drug: oxaliplatin · Drug: 5-FU · Drug: Folinic Acid

  • Experimental
    mFOLFOX6 + aflibercept

    modified FOLFOX6 chemotherapy regimen in combination with aflibercept

    Drug: aflibercept · Drug: oxaliplatin · Drug: 5-FU · Drug: Folinic Acid

Interventions

  • administration: IV infusion

    Also known as: ZALTRAP™, AVE0005

  • administration: IV infusion

  • Drug5-FU

    administration: IV infusion

  • administration: IV infusion

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) Rate at 12 Months

    PFS rate at 12 months was defined as the percentage of patients alive without disease progression at 12 months after randomization. The primary efficacy analysis was based on assessment by the Independent Review Committee (IRC). The study was not powered for comparison of PFS rate at 12 months between the two arms (non-comparative, open-label study). Progression was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.0), as at least a 20 percent increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions.

    Time frame: 12 months

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the time from the date of randomization to the date of tumor progression or death from any cause, whichever occurred first. PFS was based on tumor assessment by the Independent Review Committee (IRC). PFS was estimated from Kaplan-Meier Curves. The study was not powered for comparison of PFS between the two arms (non-comparative, open-label study). Progression was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.0), as at least a 20 percent increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions.

    Time frame: From the date of the first randomization until the study data cut-off date, 14 April 2011 (approximately 26 months)

  2. Overall Objective Response Rate (ORR)

    Summary of overall objective response rate based on tumor assessment by the Independent Review Committee (IRC) as per Response Evaluation Criteria in Solid Tumours (RECIST) criteria. ORR was defined as the proportion of patients with confirmed Complete Response (CR) or confirmed Partial Response (PR) relative to the total number of patients in the analysis population. Per RECIST v 1.0 target lesions evaluation and assessed by tumor imaging: Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): \>=30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. The study was not powered for comparison of ORR between the two arms (non-comparative, open-label study).

    Time frame: From the date of the first randomization until the study data cut-off date, 14 April 2011 (approximately 26 months)

  3. Overall Survival (OS)

    Overall survival was defined as the time from the date of randomization to the date of death due to any cause. In absence of confirmation of death, survival time was censored at the earliest between the last date the patient was known to be alive and the study cutoff date. The study was not powered for comparison of OS between the two arms (non-comparative, open-label study).

    Time frame: From the date of the first randomization until the study data cut-off date, 14 April 2011 (approximately 26 months)

  4. Number of Participants With Treatment-emergent Adverse Events (TEAE)

    Summary of treatment-emergent adverse events in the safety population. The National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE), version 3.0 was used in this study to grade the severity of AEs.

    Time frame: From the date of the first randomization up to 30 days after the treatment discontinuation or until TEAE was resolved or stabilized

  5. Immunogenicity of Intravenous (IV) Aflibercept

    The antidrug antibody (ADA) assay was evaluated for participants receiving aflibercept.

    Time frame: Any time post baseline and 90 days after the last infusion of aflibercept, according to baseline status

07

Results

Posted Jun 25, 2013
Limitations and caveats
The overall survival (OS) data are severely limited due to the low number of events (\<50%) in both arms, therefore median OS cannot be accurately estimated due to limitations of available data.

Participant flow

Participant flow — Overall Study
MilestonemFOLFOX6 OnlymFOLFOX6 + Aflibercept
Started117119
Completed00
Not completed117119
Withdrew: Randomized but not treated10
Withdrew: Adverse event2636
Withdrew: Disease progression5247
Withdrew: Poor compliance to protocol11
Withdrew: Physician decision1314
Withdrew: Consent withdrawn02
Withdrew: Withdrawal by subject1112
Withdrew: Metastatic surgery66
Withdrew: Other71

Outcome measures

PrimaryProgression Free Survival (PFS) Rate at 12 Months

PFS rate at 12 months was defined as the percentage of patients alive without disease progression at 12 months after randomization. The primary efficacy analysis was based on assessment by the Independent Review Committee (IRC). The study was not powered for comparison of PFS rate at 12 months between the two arms (non-comparative, open-label study). Progression was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.0), as at least a 20 percent increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions.

Time frame:
12 months
Reported as:
Number · percentage of participants
Progression Free Survival (PFS) Rate at 12 Months
percentage of participantsmFOLFOX6 OnlymFOLFOX6 + Aflibercept
Progression Free Survival (PFS) Rate at 12 Months21.2 (12.2 to 30.3)25.8 (17.2 to 34.4)
SecondaryProgression Free Survival (PFS)

PFS was defined as the time from the date of randomization to the date of tumor progression or death from any cause, whichever occurred first. PFS was based on tumor assessment by the Independent Review Committee (IRC). PFS was estimated from Kaplan-Meier Curves. The study was not powered for comparison of PFS between the two arms (non-comparative, open-label study). Progression was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.0), as at least a 20 percent increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions.

Time frame:
From the date of the first randomization until the study data cut-off date, 14 April 2011 (approximately 26 months)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsmFOLFOX6 OnlymFOLFOX6 + Aflibercept
Progression Free Survival (PFS)8.77 (7.622 to 9.265)8.48 (7.885 to 9.922)
SecondaryOverall Objective Response Rate (ORR)

Summary of overall objective response rate based on tumor assessment by the Independent Review Committee (IRC) as per Response Evaluation Criteria in Solid Tumours (RECIST) criteria. ORR was defined as the proportion of patients with confirmed Complete Response (CR) or confirmed Partial Response (PR) relative to the total number of patients in the analysis population. Per RECIST v 1.0 target lesions evaluation and assessed by tumor imaging: Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): \>=30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. The study was not powered for comparison of ORR between the two arms (non-comparative, open-label study).

Time frame:
From the date of the first randomization until the study data cut-off date, 14 April 2011 (approximately 26 months)
Reported as:
Number · percentage of participants
Overall Objective Response Rate (ORR)
percentage of participantsmFOLFOX6 OnlymFOLFOX6 + Aflibercept
Overall Objective Response Rate (ORR)45.9 (36.4 to 55.7)49.1 (39.7 to 58.6)
SecondaryOverall Survival (OS)

Overall survival was defined as the time from the date of randomization to the date of death due to any cause. In absence of confirmation of death, survival time was censored at the earliest between the last date the patient was known to be alive and the study cutoff date. The study was not powered for comparison of OS between the two arms (non-comparative, open-label study).

Time frame:
From the date of the first randomization until the study data cut-off date, 14 April 2011 (approximately 26 months)
Reported as:
Median · months
Overall Survival (OS)
monthsmFOLFOX6 OnlymFOLFOX6 + Aflibercept
Overall Survival (OS)22.31 (15.57 to NA)19.45 (15.64 to NA)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAE)

Summary of treatment-emergent adverse events in the safety population. The National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE), version 3.0 was used in this study to grade the severity of AEs.

Time frame:
From the date of the first randomization up to 30 days after the treatment discontinuation or until TEAE was resolved or stabilized
Reported as:
Number · participants
Number of Participants With Treatment-emergent Adverse Events (TEAE)
participantsmFOLFOX6 OnlymFOLFOX6 + Aflibercept
Treatment Emergent Adverse Event (TEAE)115119
Grade 3-4 TEAE87108
Treatment emergent Serious Adverse Event (SAE)3255
TEAE leading to death28
Premature treatment discontinuationNA34
Permanent treatment discontinuation2637
SecondaryImmunogenicity of Intravenous (IV) Aflibercept

The antidrug antibody (ADA) assay was evaluated for participants receiving aflibercept.

Time frame:
Any time post baseline and 90 days after the last infusion of aflibercept, according to baseline status
Reported as:
Number · participants
Immunogenicity of Intravenous (IV) Aflibercept
participantsNegative or MissingPositive
ADA Negative post-baseline1051
ADA Positive (drug specific) post-baseline72
ADA Negative 90 days after last dose451
ADA Positive 90 days after last dose01

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
mFOLFOX6 Only—32/116 (27.6%)114/116 (98.3%)
mFOLFOX6 + Aflibercept—55/119 (46.2%)117/119 (98.3%)
Most frequent serious events
Showing 10 of 89
Most frequent serious events
EventmFOLFOX6 OnlymFOLFOX6 + Aflibercept
PyrexiaGeneral disorders3/1166/119
Intestinal obstructionGastrointestinal disorders4/1162/119
PneumoniaInfections and infestations1/1164/119
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/1164/119
Disease progressionGeneral disorders1/1164/119
Catheter site infectionInfections and infestations3/1163/119
DiarrhoeaGastrointestinal disorders3/1163/119
Colonic obstructionGastrointestinal disorders3/1160/119
NeutropeniaBlood and lymphatic system disorders1/1163/119
Drug hypersensitivityImmune system disorders0/1163/119
Most frequent other events
Showing 10 of 59
Most frequent other events
EventmFOLFOX6 OnlymFOLFOX6 + Aflibercept
DiarrhoeaGastrointestinal disorders51/11669/119
NeutropeniaBlood and lymphatic system disorders64/11653/119
HypertensionVascular disorders8/11664/119
NauseaGastrointestinal disorders62/11662/119
StomatitisGastrointestinal disorders44/11660/119
Decreased appetiteMetabolism and nutrition disorders37/11641/119
FatigueGeneral disorders30/11641/119
HeadacheNervous system disorders9/11639/119
ConstipationGastrointestinal disorders31/11637/119
Peripheral sensory neuropathyNervous system disorders35/11623/119

Baseline characteristics

Age, Continuous
Age, Continuous(Years)mFOLFOX6 OnlymFOLFOX6 + AfliberceptTotal
Mean62.4 ± 9.761.8 ± 9.062.1 ± 9.4
Age, Customized
Age, Customized(Participants)mFOLFOX6 OnlymFOLFOX6 + AfliberceptTotal
<656570135
>=65 but <75434588
>=759413
Sex: Female, Male
Sex: Female, Male(Participants)mFOLFOX6 OnlymFOLFOX6 + AfliberceptTotal
Female494392
Male6876144
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)mFOLFOX6 OnlymFOLFOX6 + AfliberceptTotal
Caucasian/White9097187
Black011
Asian/Oriental272047
Other011
Region of Enrollment
Region of Enrollment(participants)mFOLFOX6 OnlymFOLFOX6 + AfliberceptTotal
United Kingdom222850
Korea, Republic of262046
Germany182442
Spain241842
Russian Federation151530
Italy10515
Australia2911
Body Surface Are (BSA)
Body Surface Are (BSA)(m^2)mFOLFOX6 OnlymFOLFOX6 + AfliberceptTotal
Mean1.8 ± 0.21.8 ± 0.21.8 ± 0.2
08

Study locations

37 sites
  • Sanofi-Aventis Investigational Site Number 036004
    Douglas, 4814, Australia
  • Sanofi-Aventis Investigational Site Number 036001
    Hunter Region Mail Centre, 2310, Australia
  • Sanofi-Aventis Investigational Site Number 036003
    Hunter Region Mail Centre, 2310, Australia
  • Sanofi-Aventis Investigational Site Number 276003
    Berlin, 13353, Germany
  • Sanofi-Aventis Investigational Site Number 276007
    Dresden, 01307, Germany
  • Sanofi-Aventis Investigational Site Number 276001
    Hannover, 30625, Germany
  • Sanofi-Aventis Investigational Site Number 276006
    Homberg, 66421, Germany
  • Sanofi-Aventis Investigational Site Number 276004
    Mannheim, 68167, Germany
  • Sanofi-Aventis Investigational Site Number 276002
    Münster, 48149, Germany
  • Sanofi-Aventis Investigational Site Number 276005
    Recklinghausen, 45659, Germany
  • Sanofi-Aventis Investigational Site Number 380005
    Bari, 70126, Italy
  • Sanofi-Aventis Investigational Site Number 380001
    Firenze, 50141, Italy
  • Sanofi-Aventis Investigational Site Number 380002
    Milano, 20121, Italy
  • Sanofi-Aventis Investigational Site Number 380003
    Taormina, 98039, Italy
  • Sanofi-Aventis Investigational Site Number 380004
    Torino, 10126, Italy
  • Sanofi-Aventis Investigational Site Number 410003
    Busan, 614-735, Korea, Republic of
  • Sanofi-Aventis Investigational Site Number 410004
    Cheongju, 361-711, Korea, Republic of
  • Sanofi-Aventis Investigational Site Number 410005
    Daegu, 700-721, Korea, Republic of
  • Sanofi-Aventis Investigational Site Number 410002
    Daejeon, Korea, Republic of
  • Sanofi-Aventis Investigational Site Number 410007
    Goyang-Si, Gyeonggi-Do, 410-769, Korea, Republic of
  • Sanofi-Aventis Investigational Site Number 410006
    Seoul, 120-752, Korea, Republic of
  • Sanofi-Aventis Investigational Site Number 410001
    Seoul, 152-703, Korea, Republic of
  • Sanofi-Aventis Investigational Site Number 410008
    Ulsan, 682-714, Korea, Republic of
  • Sanofi-Aventis Investigational Site Number 643002
    Pyatigorsk, 357500, Russian Federation
  • Sanofi-Aventis Investigational Site Number 643005
    Saint-Petersburg, 197758, Russian Federation
  • Sanofi-Aventis Investigational Site Number 643001
    Sochi, 354057, Russian Federation
  • Sanofi-Aventis Investigational Site Number 724005
    Barcelona, 08036, Spain
  • Sanofi-Aventis Investigational Site Number 724004
    Madrid, 28007, Spain
  • Sanofi-Aventis Investigational Site Number 724001
    Madrid, 28040, Spain
  • Sanofi-Aventis Investigational Site Number 724002
    Sabadell, 08208, Spain
  • Sanofi-Aventis Investigational Site Number 724007
    Santiago De Compostela, 15706, Spain
  • Sanofi-Aventis Investigational Site Number 724003
    Valencia, 46009, Spain
  • Sanofi-Aventis Investigational Site Number 826004
    Leeds, LS9 7TF, United Kingdom
  • Sanofi-Aventis Investigational Site Number 826001
    Leicester, LE1 5WW, United Kingdom
  • Sanofi-Aventis Investigational Site Number 826002
    Manchester, M20 4BX, United Kingdom
  • Sanofi-Aventis Investigational Site Number 826003
    Slough, SL2 4HL, United Kingdom
  • Sanofi-Aventis Investigational Site Number 826005
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Publications

  • Folprecht G, Pericay C, Saunders MP, Thomas A, Lopez Lopez R, Roh JK, Chistyakov V, Hohler T, Kim JS, Hofheinz RD, Ackland SP, Swinson D, Kopp M, Udovitsa D, Hall M, Iveson T, Vogel A, Zalcberg JR. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. Ann Oncol. 2016 Jul;27(7):1273-9. doi: 10.1093/annonc/mdw176. Epub 2016 Apr 18. PubMed 27091810 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Apr 2011 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2013, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2009
First posted
Feb 25, 2009
Start
Feb 2009
Primary completionActual
Apr 2011
CompletionActual
Jan 2012
Results first posted
Jun 25, 2013
Last update
Jun 7, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00851084
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Feb 25, 2009
Start date
Feb 2009
Primary completion
Apr 2011
Completion
Jan 2012
Results posted
Jun 25, 2013
Last update
Jun 7, 2016

Study contacts

John Zalcberg, MD
principal investigator · Peter Mc Callum Cancer Centre, Melbourne, Australia

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion